Selenium or No Selenium That Is the Question in Tumor Patients: A New Controversy
|
|
- Amanda Long
- 5 years ago
- Views:
Transcription
1 Selenium or No Selenium That Is the Question in Tumor Patients: A New Controversy Integrative Cancer Therapies 9(2) The Author(s) 2010 Reprints and permission: sagepub.com/journalspermissions.nav DOI: / Ralph Muecke, MD 1, Lutz Schomburg, PhD 2, Jens Buentzel, MD 3, Klaus Kisters, MD 4, and Oliver Micke, MD 5, on behalf of the German Working Group Trace Elements and Electrolytes in Oncology AKTE Abstract The essential trace element selenium, which is a crucial cofactor in the most important endogenous antioxidative systems of the human body, is attracting more attention from both laypersons and expert groups. The interest of oncologists mainly focuses on the following clinical aspects: protection of normal tissues, sensitizing in malignant tumors, antiedematous effect, prognostic impact of selenium, and effects in primary and secondary cancer prevention. Selenium is a constituent of the small group of selenocysteine-containing selenoproteins and elicits important structural and enzymatic functions. Selenium deficiency has been linked to increased infection risk and adverse mood states. It has been shown to possess cancer-preventive and cytoprotective activities in both animal models and humans. It is well established that it has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism, and protection against DNA damage. Recent clinical trials have shown the importance of selenium in clinical oncology. In 2009, a significant benefit of sodium selenite supplementation with no protection of tumor cells, which is often suspected by oncologists was shown in a prospective randomized trial in gynecologic cancer patients undergoing radiation therapy. More recently, concerns arose from 2 large clinical prevention trials (NPC, SELECT) that selenium may increase the risk of developing type 2 diabetes. Despite obvious flaws in both studies and good counterarguments, controversy remains on the possible advantages and risks of selenium in cancer prevention. However, in the light of the recent clinical trials the potential benefits of selenium supplementation in tumor patients are becoming obvious, even though further research is needed. Keywords selenium, tumor patients, radioprotection, cytoprotection, primary and secondary cancer prevention The essential trace element selenium (Se) is of fundamental importance to human health. As a constituent of the small group of selenocysteine-containing selenoproteins, Se elicits important structural and enzymatic functions. 1,2 Se deficiency has been linked to increased infection risk and adverse mood states. 3 It is well established that Se has a key role in redox regulation and antioxidant function, and hence in membrane integrity, energy metabolism, and protection against DNA damage. These and other functions are mediated through a small number of approximately 50 different selenoproteins encoded by 25 separate genes, which require adequate Se availability for their regular biosynthesis and expression. Selenoproteins include several forms of the enzymes glutathione peroxidase (GPx), thioredoxin reductase, and iodothyronine deiodinase. 1,2 Plasma Se concentration is the most commonly used indicator of Se status. The normal level depends on the geographical region, the relative amount of selenomethionine consumed and on the personal genotype controlling selenoprotein expression. 4-6 Therefore, different methods and biomarkers are currently used in parallel to define the Se status of an individual person. 7 Nevertheless, in the majority of the published work a normal level of approximately 60 to 120 mg/l Se in plasma or serum (corresponding to approximately 1 Lippe Hospital, Lemgo, Germany 2 Charité Berlin, Berlin, Germany 3 Suedharz Hospital, Nordhausen, Germany 4 St Anna Hospital, Herne, Germany 5 Franziskus Hospital, Bielefeld, Germany Corresponding Author: Oliver Micke, Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Kiskerstrasse 26, D Bielefeld, Germany strahlenklinik@web.de
2 Muecke et al to 151 mg/l in whole blood) is given. Nutritional Se intake, plasma Se concentration, and GPx activity display a positive correlation up to a threshold plasma Se concentration (70 to 100 mg/l), beyond which the GPx activity plateaus. 8 This maximum GPx concentration is thought to represent repletion, and commensurate Se intake forms the basis for the recommended dietary requirement. Concentrations of other selenoproteins are also influenced by Se intake and may represent even better functional indicators of Se status, but assay methods and reference standards are at an early stage, and comparisons between different studies are difficult. There is a certain hierarchical expression of the selenoproteins, with relative preservation of the presumably more metabolically important members at lower intakes of Se. Moreover, male and female organisms differ in their regulation of selenoprotein expression and epidemiological and intervention studies correlating health effects with Se status highlighted some important differences between the sexes. 9 Thus, we are far from understanding the health implications of suboptimal expression of the selenoproteins in humans. 3,10,11 Various epidemiological and experimental studies have shown an association between low Se levels and increased cancer incidence. 3,12-17 In this context, some authors have correlated the decreased levels of Se in blood, serum, or plasma with reduced Se-dependent enzymatic antioxidant capacities in patients with malignant diseases. 15,16 The issue of whether this difference is secondary to the malignancy or represents a predisposing factor leading to higher cancer incidence is at present unresolved. Furthermore, the potential of Se as a natural anticancer agent is well documented by several clinical interventional trials. 18,19 Secondary findings from the 10-year US Nutritional Prevention of Cancer (NPC) Trial demonstrated a protective effect of supplementation with 200 mg/day of organic Se (from yeast) on total cancer incidence and mortality, 18 and on prostate cancer (relative risk 0.51 and 95% confidence interval ) with the strongest effect in men with lower baseline plasma Se levels (<123 mg/l). 20 There are numerous limitations to what was intended as a prospective study to prevent nonmelanoma skin cancer, and the relatively high baseline plasma Se levels (115.1 mg/l) make it difficult to generalize the findings. Nevertheless, the results of the NPC trial remain under discussion. 18 It appears that protection from cancer may require a Se supplementation dosage beyond correction of submaximal GPx expression potentially needed for a maximal expression of other selenoproteins, which cannot easily be measured from plasma samples. Beside the antioxidative capacity in the healthy tissue via increased biosynthesis of the different GPx and thioredoxin reductase isoenzymes, a selective unusual activation of wild-type p53 in healthy cells by Se-dependent reduction of 2 critical cysteine residues by Ref 1 might be responsible for consecutive activation of DNA-repair. 21,22 In addition, Se may reduce translocation of the inflammatory transcription factor NFkB into the nucleus and thereby reduce cytokine production and release. 23,24 Radiotherapy and chemotherapy as well as the suboptimal nutrition of cancer patients in the clinic might aggravate the situation in a Se-deficient patient even further, and increase the likelihood of radiation-induced side effects during and after therapy Preliminary experimental and clinical evidence indicate that Se might function as an effective radioprotector and chemoprotector with the ability to alleviate side effects of tumor specific chemotherapy or radiotherapy treatments In 2003, an English retrospective study indicated a positive correlation between initial serum Se levels and the dose delivery of chemotherapy and outcome in patients with aggressive non-hodgkin s lymphoma. 37 In light of the results of a follow-up experimental study the authors concluded that the Se compounds methylseleninic acid (MSA) and selenodiglutathione (SDG) induce cell death in lymphoma cell lines and primary lymphoma cultures, which may be partly attributable to the generation of reactive oxygen species. 38 A randomized study in postoperative gynecological patients with supplementation of Se under radiotherapy conditions supported these findings. In particular, the patients with higher plasma and whole blood Se levels tolerated the side effects of radiotherapy significantly better, without any obvious impairment of survival data. The aim of the study was to assess whether adjuvant supplementation with Se improves the Se status and reduces the radiation-induced side effects of patients treated by pelvic radiotherapy for cervical and uterine cancer. A total of 81 patients were randomized of whom 39 were enrolled in the Se group (SG) and 42 in the control group (CG). Plasma and whole blood Se concentrations increased in the SG and the actuarial incidence of at least grade 2 diarrhea was significantly reduced compared with the CG. The 5-year overall survival rate of patients in the SG was calculated to be 92% compared with 83% in the CG (P =.34). 39 A nonlinear association between serum Se levels and allcause and cancer mortality was published by Bleys et al 40 in 2008 based on the analysis of a representative sample of the US population with 13,887 adult participants. Increased serum Se levels were associated with decreased mortality up to concentrations of 130 mg/l. Some analyses, however, raised the concern that higher serum Se levels may be associated with increased mortality. 40 In October 2008, the abrogation of the so called Selenium and Vitamin E Cancer Prevention Trial (SELECT) was announced because of a number of reasons. In the intervention group of this prostate cancer prevention trial
3 138 Integrative Cancer Therapies 9(2) with selenomethionine supplementation, no positive effect on prostate cancer incidence was detected. 41 Moreover, a small and nonsignificant rise in the incidence of type 2 diabetes mellitus was observed. Some potential issues need to be mentioned with respect to these surprising null results when supplementation attempts in the context of oncology are discussed. First, the supplementation during the SELECT study was based on organic selenomethionine in contrast to Se-enriched yeast as used before in the aforementioned and positive NPC trial. Here, a number of yeast-specific Se-dependent compounds might have been missing, which might have contributed to the lack of chemopreventive activity observed. Moreover, selenomethionine-based supplementation trials are always very difficult to interpret, because the supplement is incorporated nonspecifically into non-selenoenzymes because of its similarity to normal sulfur-methionine. The effect of selenomethionine on the expression of selenoenzymes cannot be predicted or measured from patients blood samples. Therefore, it appears as if choosing sodium selenite as a supplement might represent a better alternative, because the effects of the supplementation can be verified by increased serum Se or circulating selenoprotein concentrations. Second, the dosage management of an adjuvant longterm Se therapy should always be done according to the measured whole blood or serum Se or selenoprotein values. The study population in the SELECT trial initially showed a baseline serum Se level of about 135 mg/l (corresponding to approximately 170 mg/l in whole blood and in accordance with published values 7 ) and after supplementation reached abnormally high serum values of approximately 250 mg/l. 41 There is currently no convincing rationale to administer Se to already well-supplied individuals. Third, it must be taken into account that diabetes risk was not a primary study endpoint, and therefore, the trial was not stratified according to the common risk factors for type 2 diabetes, for example, body mass index. Furthermore, the trial was criticized for its 2 2 factorial design, which is not optimally suited for the central study question, because there is only one arm using Se alone. Moreover, scientific data to estimate the potential interactions of the vitamin E and Se supplementation in the particular doses were largely missing. The interaction between 2 agents might be synergistic or additive, also with respect to any potential negative (ie, pro-oxidant) effects. 42 In particular, most adverse effects were observed in the study arms with vitamin E, which had only rarely been tested in human supplementation trials before, and which is not known to exhibit particular chemopreventive properties on prostate. It is thus presently being criticized for possible side effects or interactions. This lack of knowledge on vitamin E supplementation effects in prospective prostate cancer prevention studies and the potential risks of vitamin E and Se combinations were not adequately addressed before the trial and appear to be insufficiently discussed on ending it. In addition, the adverse findings on the vitamin E arms were oversimplified and extended to the Se arms without sufficiently differentiating between the 2 supplements. Similarly, it was not acknowledged that the SELECT study actually constituted 3 individual trials in parallel, in which only the control group was identical for the different study arms. Therefore, failure of the trial needs to be more intensively and cautiously specified with respect to the individual study arms, supplements and effects. Overall, the scientific evidence on which the study conceptual design for tumor prevention and the chosen study medication and dosages was based, was relatively low especially with respect to the vitamin E arms. Notably, the incidence or rate of occurrence of prostate cancer was not the primary focus or endpoint in any of the few randomized controlled trials on which the SELECT trial was based. In fact, an overall reduction of prostate cancer by 25% by a single agent appears much too optimistic. This assumption was based on the results of the lowest tertile in the NPC trial, 18 but Se levels this low were a minority in the SELECT population. So far, there is only one medication known that is able to reduce prostate cancer incidence by about one fourth, the 5-a-reductase inhibitor finasteride, which is generally used to treat benign prostate hyperplasia and androgenetic alopecia. On the other hand, this drug may cause several side effects, such as impotence and gynecomastia, and is suspected of creating an increased rate of high Gleason grade tumors. 43 Hence, it appears a bit too optimistic to expect such huge effects (25% less prostate cancers) just by taking 1 or 2 dietary supplements, given the thoughts summarized above. Of course, lowering the expected effect size to 20% or 15% would surely have increased the number of participants to be enrolled into an unaffordable magnitude. Concerning the supposed diabetic risk of Se, one must take into account that the absolute increase of diabetes is just 0.7% in the Se only group (10% diabetes in the verum group vs 9.3%, in the placebo group) and did not reach statistical significance (P =.16). In addition, the data were not adjusted to the general increase of diabetes in the United States (between 2001 and 2007 about 16%). Therefore, in our opinion this criterion is not appropriate to justify the discontinuation of the study. All in all, the SELECT trial is not adequate to prove either the ineffectiveness of Se to prevent prostate cancer, to estimate the hazard of Se to trigger diabetes, or to discredit Se for both. Whether surplus Se intake in already well-supplied individuals confers any health benefit or rather leads to an increased risk for developing type 2 diabetes mellitus is currently an issue of concern and intense discussion. 44
4 Muecke et al. 139 Finally, Se supplementation in the context of patients during radiotherapy and chemotherapy represents a shortterm focused intervention and not a chronic condition, in contrast to the SELECT trial. Therefore, especially with respect to the marginally supplied patients whose personal Se deficiency might be further aggravated during the course of the illness, Se supplementation effort with the aim to increase the Se status to optimal selenoprotein expression, that is, into the range of 100 mg/l Se in plasma or serum or above, appears advisable. This notion is in agreement with the large number of clinical studies correlating a reduced disease risk and a better recovery from disease with Se status at the beginning or during the course of illness. Thus, we strongly suggest measuring the Se status in tumor patients prior to and during therapy, and in the aftercare situation to avoid side effects and optimize the odds for a positive Se supplementation effect in the clinic. The most important lesson we learn from SELECT is that we must know many more details on the molecular and physiological mechanisms of Se action in the human body. With great interest, we have read the report by Chan et al 45 on the relationship between circulating Se levels at diagnosis and prognostic risk of prostate cancer as modified by the SOD2 genotype. They showed that SOD2 genotypes (AA, VA, and VV) alone were not and higher plasma Se levels alone were only slightly associated with increased risk of having aggressive prostate cancer at diagnosis. Among men with the SOD2 genotypes VA and VV, those with high versus low plasma Se levels had an increased risk of presenting with aggressive prostate cancer. 45 Some potential issues need to be mentioned with respect to these surprising new results when supplementation attempts in the context of oncology are discussed: Disregarding the patients with the VV variant of SOD2 (n = 107, 21.9%) with the highest risk of having aggressive prostate cancer at diagnosis with high versus low plasma Se levels, there is, with respect to the data of Chan et al, 45 for the other patients (n = 382, 78.1%) an increased risk only in the quintile groups IV and V with plasma Se levels higher than and mg/l, respectively. The results concerning the patients group with the VV variant of SOD2 indicate the existence of high-risk subgroups. These new findings require further confirmation. Both the results of the SELECT trial and the data of Chan et al 45 give us important information and thus confirm the results of Bleys et al. 40 Although first indications of additional factors are known, that is, different genotypes of enzymes, it seems most important to achieve and maintain a certain range of Se in the plasma. This range is most likely between 110 and 130 mg/l. For humans who are supplemented with Se sufficiently through their nutrition and thus are within the required range additional Se supplementation is not necessary; it might even be dangerous. There is currently no convincing rationale to administer Se to already well-supplied individuals. Even though there is no general recommendation in favor of or against Se supplementation in cancer patients, 46 the attempts to correct a proven suboptimal Se status prior to treatment appear justified. Therefore, we strongly advocate that physicians first determine the Se status of their patients and then take the necessary measures to improve the Se status of tumor patients under oncological therapy and in aftercare situations when Se status appears suboptimal. Declaration of Conflicting Interests The author(s) declared no potential conflicts of interest with respect to the authorship and/or publication of this article. Funding The author(s) received no financial support for the research and/or authorship of this article. References 1. Papp LV, Lu J, Holmgren A, Khanna KK. From selenium to selenoproteins: synthesis, identity, and their role in human health. Antioxid Redox Signal. 2007;9: Schomburg L, Koehrle J. Selenium: benefits and risks. MMW Fortschr Med. 2007;149: Rayman MP. The importance of selenium to human health. Lancet. 2000;356: Johnson CC, Fordyce FM, Rayman MP. Symposium on Geographical and geological influences on nutrition : Factors controlling the distribution of selenium in the environment and their impact on health and nutrition. Proc Nutr Soc. 2010;69: Schomburg L, Koehrle J. On the importance of selenium and iodine metabolism for thyroid hormone biosynthesis and human health. Mol Nutr Food Res. 2008;52: Méplan C, Nicol F, Burtle BT, et al. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal. 2009;11: Ashton K, Hooper L, Harvey LJ, Hurst R, Casgrain A, Fairweather-Tait SJ. Methods of assessment of selenium status in humans: a systematic review. Am J Clin Nutr. 2009;89: 2025S-2039S. 8. Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low-selenium area of China. Am J Clin Nutr. 2005;81: Schomburg L, Schweizer U. Hierarchical regulation of selenoprotein expression and sex-specific effects of selenium. Biochim Biophys Acta. 2009;1790: Burk RF, Hill KE, Motley AK. Plasma selenium in specific and non-specific forms. Biofactors. 2001;14:
5 140 Integrative Cancer Therapies 9(2) 11. Combs GF Jr. Selenium in global food systems. Br J Nutr. 2001;85: Brooks JD, Metter EJ, Chan DW. Plasma selenium level before diagnosis and the risk of prostate cancer development. J Urol. 2001;166: Kellen E, Zeegers M, Buntinx F. Selenium is inversely associated with bladder cancer risk: a report from the Belgian case-control study on bladder cancer. Int J Urol. 2006;13: Knekt P, Aromaa A, Mantela J. Serum selenium and subsequent risk of cancer among Finnish men and woman. J Natl Cancer Inst. 1990;82: Muecke R, Buentzel J, Glatzel M, et al. Postoperative serum and whole blood selenium levels in patients with squamous cell and adenocarcinomas of the uterus after curative surgical treatment. Trace Elem Electrolytes. 2009;26: Pawlowicz Z, Zachara BA, Trafikowska U, Maciag A, Marchaluk E, Nowicki A. Blood selenium concentrations and glutathione peroxidase activities in patients with breast cancer and with advanced gastrointestinal cancer. J Trace Elem Electrolytes Health Dis. 1991;5: Torun M, Aldemir H, Yardim S. Serum selenium levels in various cancer types. Trace Elem Electrolytes. 1995;12: Clark LC, Combs GF, Turnbull BW, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA. 1996;276: Yu SY, Zhu YJ, Li WG et al. A preliminary report on the intervention trials of primary liver cancer in high-risk populations with nutritional supplementation of selenium in China. Biol Trace Elem Res. 1991;29: Duffield-Lillico AJ, Dalkin BL, Reid ME, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int. 2003;91: Gudkov AV. Converting p53 from a killer to a healer. Nat Med. 2002;8: Fischer JL, Mihelc EM, Pollok KE, Smith ML. Chemotherapeutic selectivity conferred by selenium: a role for p53-dependent DNA repair. Mol Cancer Ther. 2007;6: Vunta H, Davis F, Palempalli UD, et al. The anti-inflammatory effects of selenium are mediated through 15-deoxy-Delta-12, 14-prostaglandin J2 in macrophages. J Biol Chem. 2007;282: Beck MA, Nelson HK, Shi Q, et al. Selenium deficiency increases the pathology of an influenza virus infection. FASEB J. 2001;15: Buentzel J, Muecke R, Micke O. Mineral status and enzymatic antioxidative capacities during radiochemotherapy in patients with advanced head and neck cancer. Trace Elem Electrolytes. 2000;18: Buentzel J, Micke O, Muecke R, et al. Amifostine and selenium during simultaneous radiochemotherapy in head and neck cancer redox status data. Trace Elem Electrolytes. 2005;22: Micke O, Buentzel J, Bruns F, et al. Clinical elementology in oncology: experiences and proposals from Germany. Trace Elements Electrolytes. 2008;25: Schueller P, Puettmann S, Muecke R, et al. From the radiolysis of water to the role of trace elements in radiobiology and clinical radiation therapy: following a logical chain. Trace Elem Electrolytes. 2001;18: Doerr W. Effects of selenium on radiation responses of tumor cells and tissue. Strahlenther Onkol. 2006;182: Funke AM. Potential of selenium in gynecological oncology. Med Klin. 1999;94: Fraunholz I, Jueling-Pohlit L, Boettcher H. Influence of selenium on acute mucositis in radiochemotherapy of head and neck tumors. Trace Elem Electrolytes. 2001;18: Gehrisch A, Doerr W. Effects of systemic or topical administration of sodium selenite on early radiation effects in mouse oral mucosa. Strahlenther Onkol. 2007;183: Hehr T, Hoffmann W, Bamberg M. Role of sodium selenite as an adjuvant in radiotherapy of rectal carcinoma. Med Klin. 1997;92(Suppl 3): Patchen ML, MacVittie TJ, Weiss JF. Combined modality radioprotection: the use of glucan and selenium with WR Int J Radiat Oncol Biol Phys. 1990;18: Vermeulen N, Baldew GS, Los G, McVie JG, De Goeij JM. Reduction of cisplatinum nephrotoxicity by sodium selenite. Drug Metabol Dispos. 1993;21: Weijl NI, Elsendoorn TJ, Lentjes EG, et al. Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study. Eur J Cancer. 2004;40: Last KW, Cornelius V, Delves T, et al. Presentation serum selenium predicts for overall survival, dose delivery, and first treatment response in aggressive non-hodgkin s lymphoma. J Clin Oncol. 2003;21: Last K, Maharaj L, Perry J, et al. The activity of methylated and non-methylated selenium species in lymphoma cell lines and primary tumours. Ann Oncol. 2006;17: Muecke R, Schomburg L, Glatzel M, et al. Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology [published ahead of print February 2, 2010]. Int J Radiat Oncol Biol Phys. doi: /j.ijrobp Bleys J, Navas-Acien A, Guallar E. Serum selenium levels and all cause, cancer, and cardiovascular mortality among US adults. Arch Intern Med. 2008;168: Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The selenium and vitamin E cancer prevention trial (SELECT). JAMA. 2009;301:39-51.
6 Muecke et al Moyad MA. Selenium and vitamin E supplements for prostate cancer: evidence or embellishment? Urology. 2002; 59(4 Suppl 1): Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS. Five-alpha-reductase inhibitors for prostate cancer prevention. Cochrane Database Syst Rev. 2008;2:CD Stranges S, Marshall JR, Natarajan R, et al. Effects of long-term selenium supplementation on the incidence of type 2 diabetes: a randomized trial. Ann Intern Med. 2007; 147: Chan JM, Oh WK, Xie W, et al. Plasma selenium, manganese superoxide dismutase, and intermediate- or high-risk prostate cancer. J Clin Oncol. 2009;27: Dennert G, Horneber M. Selenium for alleviating the side effects of chemotherapy, radiotherapy and surgery in cancer patients. Cochrane Database Syst Rev. 2006;3:CD
RALPH MUECKE 1,8, THEODOR KLOTZ 2, JOSEF GIEDL 3, JENS BUENTZEL 4,8, GUENTHER KUNDT 5, KLAUS KISTERS 6,8, FRANZ-JOSEF PROTT 1 & OLIVER MICKE 7,8
Acta Oncologica, 29; 48: 452456 ORIGINAL ARTICLE Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic
More informationSelenium, Genetic Variation, and Prostate Cancer Risk: Epidemiology Reflects Back on Selenium and Vitamin E Cancer Prevention Trial
VOLUME 27 NUMBER 22 AUGUST 1 2009 JOURNAL OF CLINICAL ONCOLOGY E D I T O R I A L Selenium, Genetic Variation, and Prostate Risk: Epidemiology Reflects Back on Selenium and Vitamin E Prevention Trial Elizabeth
More informationSelenium / selenite in cancer prevention, therapy, and aftercare
Selenium / selenite in cancer prevention, therapy, and aftercare Second version Date of literature search: 6 th June, 2014 Database: PubMed (www.ncbi.nlm.nih.gov/pubmed) Abbreviations: Se Selenium (includes
More informationSelenium what are the issues? A review of requirements relating to different clinical settings Sonia Williams
what are the issues? A review of requirements relating to different clinical settings Introduction Selenium is an essential trace element. It is required for production of 25 selenoproteins. Their functions
More informationScientists Explain How Selenium Affects Cancer
Scientists Explain How Selenium Affects Cancer 2014 Selenium and cancer: A story that should not be forgotten Insights from genomics Catherine Meplan and John Hesketh, Advances in Nutrition and Cancer,
More informationA Summary of the studies conducted with CV247
A Summary of the studies conducted with CV247 Introduction Several epidemiological studies have shown that people deficient in trace elements such as selenium, copper, manganese, and vitamins, mainly C,D
More informationSelenium biofortification and human health. Gijs Du Laing
Selenium biofortification and human health Gijs Du Laing Selenium discovered in Sweden by Jöns Jacob Berzelius (1817) impurity contaminating sulfuric acid (H 2 SO 4 ) sulphur analogue semiconductor used
More informationSelenium during cancer treatment
Concerted Action for Complementary and Alternative Medicine Assessment in the Cancer Field (CAM-Cancer) Project initiated under the European Commission 5th Framework Program "Quality of Life", now hosted
More informationNST 160 Theil Selenium Lecture 1 October 27, 2004 Selenium Nutrition and Physiology
NST 160 Theil Selenium Lecture 1 October 27, 2004 Selenium Nutrition and Physiology Reading Chapter 12: Insel, P., R.E. Turner, and D. Ross. Nutrition, 2nd Ed. Chapter 34: (Reserve BioSci Library) Stipanuk
More informationAssessment of requirements for selenium and adequacy of selenium status: a review
(2004) 58, 391 402 & 2004 Nature Publishing Group All rights reserved 0954-3007/04 $25.00 www.nature.com/ejcn REVIEW Assessment of requirements for selenium and adequacy of selenium status: a review 1
More informationOH-selenomethionine: an efficient source of Se in fattening pigs
OH-selenomethionine: an efficient source of Se in fattening pigs S. GREEN, K. COPPENS, P.-A. GERAERT Adisseo France SAS and Denkavit BV, Netherlands What are our challenges at the animal level? Pork: Transform
More informationSelenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers. Key Points
CANCER FACTS N a t i o n a l C a n c e r I n s t i t u t e N a t i o n a l I n s t i t u t e s o f H e a l t h D e p a r t m e n t o f H e a l t h a n d H u m a n S e r v i c e s Selenium and Vitamin E
More informationThis student paper was written as an assignment in the graduate course
77:222 Spring 2005 Free Radicals in Biology and Medicine Page 0 This student paper was written as an assignment in the graduate course Free Radicals in Biology and Medicine (77:222, Spring 2005) offered
More informationImpact of Dietary Selenium on Meat Quality. Juan Gomez-Basauri, Ph.D.
Impact of Dietary Selenium on Meat Quality Juan Gomez-Basauri, Ph.D. Meat Quality Characteristics Appearance Color Tenderness Texture Flavor Aroma Purchasing Decision Color Oxidative Stability Oxidative
More informationEstablishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial 1 4
Establishing optimal selenium status: results of a randomized, double-blind, placebo-controlled trial 1 4 Rachel Hurst, Charlotte N Armah, Jack R Dainty, Dave J Hart, Birgit Teucher, Andrew J Goldson,
More informationUpdates on clinical studies of selenium supplementation in radiotherapy
Puspitasari et al. Radiation Oncology 2014, 9:125 REVIEW Updates on clinical studies of selenium in Open Access Irma M Puspitasari 1,2, Rizky Abdulah 1,2, Chiho Yamazaki 1, Satomi Kameo 1, Takashi Nakano
More informationStudies of Human Maximal and Minimal Safe Intake and Requirement of Selenium
Studies of Human Maximal and Minimal Safe Intake and Requirement of Selenium G. YANO,,2, L. Gu', R. ZHOU', and S. YIN' 1 Introduction Although the geographical relationship between human cancer incidence
More informationProceedings of the 36th World Small Animal Veterinary Congress WSAVA
www.ivis.org Proceedings of the 36th World Small Animal Veterinary Congress WSAVA Oct. 14-17, 2011 Jeju, Korea Next Congress: Reprinted in IVIS with the permission of WSAVA http://www.ivis.org 14(Fri)
More informationRisks and benefits of weight loss: challenges to obesity research
European Heart Journal Supplements (2005) 7 (Supplement L), L27 L31 doi:10.1093/eurheartj/sui083 Risks and benefits of weight loss: challenges to obesity research Donna Ryan* Pennington Biomedical Research
More informationYiming Xia, Kristina E Hill, Ping Li, Jiayuan Xu, Dingyou Zhou, Amy K Motley, Li Wang, Daniel W Byrne, and Raymond F Burk
Optimization of selenoprotein P and other plasma selenium biomarkers for the assessment of the selenium nutritional requirement: a placebo-controlled, double-blind study of selenomethionine supplementation
More informationSelenium and Vitamin E Cancer Prevention Trial (SELECT): Questions and Answers
1 FOR IMMEDIATE RELEASE: Monday, October 27, 2008 CONTACT: NCI Office of Media Relations (301) 496-6641 ncipressofficers@mail.nih.gov University of Michigan Nicole Fawcett (734) 764-2220 nfawcett@med.umich.edu
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationDEPARTMENT OF ONCOLOGY ELECTIVE
DEPARTMENT OF ONCOLOGY ELECTIVE 2015-2016 www.uwo.ca/oncology Oncology Elective Program Administrator: Ms. Kimberly Trudgeon Room A4-901C (Admin) LHSC London Regional Cancer Centre (Victoria Campus) Phone:
More informationOral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance for Localized Prostate Cancer
Published OnlineFirst on July 20, 2010 as 10.1158/1940-6207.CAPR-09-0143 Research Article Oral Selenium Supplementation Has No Effect on Prostate- Specific Antigen Velocity in Men Undergoing Active Surveillance
More informationProviding Treatment Information for Prostate Cancer Patients
Providing Treatment Information for Prostate Cancer Patients For all patients with localized disease on biopsy For all patients with adverse pathology after prostatectomy See what better looks like Contact
More informationHyperthermia as an integral component of multimodal treatment concepts:
Hyperthermia as an integral component of multimodal treatment concepts: Current development in Europe German Society for Radiation Oncology/Austrian Society for Radiation Oncology convention 2008 Vienna,
More informationNUTRITIONAL ASPECTS OF SELENIUM (SE)
NUTRITIONAL ASPECTS OF SELENIUM (SE) B. Ruseva 1 and F. Ribarova 2 1 Medical University Pleven, 2 Medical University So a Summary. The aim of this study is to present the current scienti c achievements
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationABSTRACT. defenses against cancer, we asked whether T cell immunity can modulate selenium
ABSTRACT Title: EFFECT OF DIETARY SELENIUM STATUS ON T CELL IMMUNITY AND CANCER XENOGRAFT IN NUDE MICE Alexandra Holmstrom, Master of Science, 2010 Directed By: Assistant Professor Wen-Hsing Cheng, Department
More informationEstrogen. Cysteine Prevents oxidation of estrogen into a dangerous form that causes breast cancer. 29,30,31
Cysteine Prevents oxidation of estrogen into a dangerous form that causes breast cancer. 29,30,31 Estrogen lowers risk of zinc de ciency; dependent proteins metabolize estrogen. 26,27,28 Magnesium Cofactor
More informationGlutathione / Thioredoxin Nrf2 & Hyperoxia
Glutathione / Thioredoxin Nrf2 & Hyperoxia Trent E. Tipple, MD Principal Investigator, Center for Perinatal Research The Research Institute at Nationwide Children s Hospital Assistant Professor of Pediatrics,
More informationSubject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49
OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection
More informationChallenges in setting Dietary Reference Values. Where to go from here? Inge Tetens & Susan Fairweather-Tait
Challenges in setting Dietary Reference Values. Where to go from here? Inge Tetens & Susan Fairweather-Tait EFSA symposium on DRVs at FENS Berlin, 22 October 2015 Conflict of interest regarding this presentation:
More informationEcologic Study of Serum Selenium and Upper Gastrointestinal Cancers in Iran
Serum Selenium and Upper GI Cancers Nouraie M Pourshams A Kamangar F Mir-Nasseri MM Sotoudeh M Derakhshan MH Akbari MR Fakheri H Mazandaran University of Medical Zahedi MJ Kerman University of Medical
More informationPLACE OF SELENIUM IN THE TREATMENT OF THYROID DISEASES
VII, 2013, 2 27, PLACE OF SELENIUM IN THE TREATMENT OF THYROID DISEASES D. Gavrailova Faculty of Public Health, Medical University So a : (Se).,. Se, - (, )., Se., Se -. :,,, :,, Summary: The essential
More informationAdjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain
Adjuvant and neoadjuvant chemotherapy for rectal cancer: Expensive but little gain Outline The problem Adjuvant therapy Neoadjuvant therapy Options Conclusion The problem 30 years ago: Local recurrence
More informationPredictive Assays in Radiation Therapy
Outline Predictive Assays in Radiation Therapy Radiation Biology Introduction Early predictive assays Recent trends in predictive assays Examples for specific tumors Summary Lecture 4-23-2014 Introduction
More informationChemo-endocrine prevention of breast cancer
Chemo-endocrine prevention of breast cancer Andrea DeCensi, MD Division of Medical Oncology Ospedali Galliera, Genova; Division of Cancer Prevention and Genetics, European Institute of Oncology, Milano;
More informationFruit & Vegetable Consumption and Mental Health
Fruit & Vegetable Consumption and Mental Health Saverio Stranges, MD, PhD, FAHA Department of Epidemiology & Biostatistics, Western University Department of Family Medicine, Western University Department
More informationGrand Unified Mineral Complex
Grand Unified Mineral Complex By Dr. Richard N. Olree jr Dr. Olree s Grand Unified Mineral Complex was designed to provide the greatest impact on human health with the most important minerals needed for
More informationCarcinosarcoma Trial rial in s a in rare malign rare mali ancy
Carcinosarcoma Trials in a rare malignancy BACKGROUND Rare and highly aggressive epithelial malignancies Biphasic tumors with epithelial and mesenchymal components Uterine carcinomas (UCS) uncommon with
More informationAccelerating Innovation in Statistical Design
Implementing a National Cancer Clinical Trials System for the 21 st Century, Workshop #2 Session #5: Accelerating Innovation Through Effective Partnerships Accelerating Innovation in Statistical Design
More informationSelenium status and risk of prostate cancer in a Danish population
Downloaded from orbit.dtu.dk on: Jul 23, 2018 Selenium status and risk of prostate cancer in a Danish population Outzen, Malene; Tjønneland, Anne; Larsen, Erik Huusfeldt; Friis, Søren ; Larsen, Signe B.;
More informationComparison of Futility Monitoring Methods Using RTOG Clinical Trials. Q. Ed Zhang, PhD
Comparison of Futility Monitoring Methods Using RTOG Clinical Trials Q. Ed Zhang, PhD 1 Futility Monitoring Definition: Monitoring for early determination that trial results will not be in favor of H 1
More informationDepartment of Radiotherapy & Nuclear Medicine, National Cancer Institute, Cairo University, Cairo, Egypt.
Original article Res. Oncol. Vol. 12, No. 1, Jun. 2016:10-14 Dosimetric comparison of 3D conformal conventional radiotherapy versus intensity-modulated radiation therapy both in conventional and high dose
More informationHPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view. Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium
HPV INDUCED OROPHARYNGEAL CARCINOMA radiation-oncologist point of view Prof. dr. Sandra Nuyts Dep. Radiation-Oncology UH Leuven Belgium DISCLOSURE OF INTEREST Nothing to declare HEAD AND NECK CANCER -HPV
More informationThe cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y
The cost of prostate cancer chemoprevention: a decision analysis model Svatek R S, Lee J J, Roehrborn C G, Lippman S M, Lotan Y Record Status This is a critical abstract of an economic evaluation that
More informationInteraction of Nutrition and Health in Cows. Dr. Matt Hersom Extension Beef Cattle Specialist Dept. of Animal Sciences
Interaction of Nutrition and Health in Cows Dr. Matt Hersom Extension Beef Cattle Specialist Dept. of Animal Sciences Overview Why is nutrition important for immunity What nutrients are utilized for immunity
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationOutcomes Following Negative Prostate Biopsy for Patients with Persistent Disease after Radiotherapy for Prostate Cancer
Clinical Urology Post-radiotherapy Prostate Biopsy for Recurrent Disease International Braz J Urol Vol. 36 (1): 44-48, January - February, 2010 doi: 10.1590/S1677-55382010000100007 Outcomes Following Negative
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationImproving quality of care for patients with ovarian and endometrial cancer Eggink, Florine
University of Groningen Improving quality of care for patients with ovarian and endometrial cancer Eggink, Florine IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if
More informationThe problem of uncontrolled hypertension
(2002) 16, S3 S8 2002 Nature Publishing Group All rights reserved 0950-9240/02 $25.00 www.nature.com/jhh The problem of uncontrolled hypertension Department of Public Health and Clinical Medicine, Norrlands
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationSmoking, human papillomavirus infection, and p53 mutation as risk factors in oropharyngeal cancer: a case-control study
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Smoking, human papillomavirus infection, and p53 as risk factors in oropharyngeal cancer: a case-control study PKS Chan *, JSY Chor, AC Vlantis, TL
More informationSelenium and Bladder Cancer Risk: a Meta-analysis
Published OnlineFirst on August 31, 2010 as 10.1158/1055-9965.EPI-10-0544 Research Article Selenium and Bladder Cancer Risk: a Meta-analysis Cancer Epidemiology, Biomarkers & Prevention André F.S. Amaral
More informationMetachronous anterior urethral metastasis of prostatic ductal adenocarcinoma
http://dx.doi.org/10.7180/kmj.2016.31.1.66 KMJ Case Report Metachronous anterior urethral metastasis of prostatic ductal adenocarcinoma Jeong Hyun Oh 1, Taek Sang Kim 1, Hyun Yul Rhew 1, Bong Kwon Chun
More informationSulfur in human nutrition and applications in medicine.
Altern Med Rev. 2002 Feb;7(1):22-44. Sulfur in human nutrition and applications in medicine. Parcell S. American Institute for Biosocial and Medical Research (AIBMR), Tacoma, WA, USA. steveparcell@attbi.com
More informationUsing Electronic Health Records to Assess Depression and Cancer Comorbidities
236 Informatics for Health: Connected Citizen-Led Wellness and Population Health R. Randell et al. (Eds.) 2017 European Federation for Medical Informatics (EFMI) and IOS Press. This article is published
More informationUtility of 18 F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer
Utility of F-FDG PET/CT in metabolic response assessment after CyberKnife radiosurgery for early stage non-small cell lung cancer Ngoc Ha Le 1*, Hong Son Mai 1, Van Nguyen Le 2, Quang Bieu Bui 2 1 Department
More informationNational Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: (V2)
National Cancer Registration and Analysis Service Short Report: Chemotherapy, Radiotherapy and Surgical Tumour Resections in England: 13-14 (V2) Produced as part of the Cancer Research UK - Public Health
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationChapter 10. Summary, conclusions and future perspectives
Chapter 10 Summary, conclusions and future perspectives 10.1 SUMMARY In this thesis, a new tumor imaging tracer in nuclear medicine is studied. This 123 tracer, L-3-[ I]Iodo-alpha-methyl-tyrosine (IMT),
More informationNeoadjuvant therapy a new pathway to registration?
Neoadjuvant therapy a new pathway to registration? Graham Ross, FFPM Clinical Science Leader Roche Products Ltd Welwyn Garden City, UK (full time employee) Themes Neoadjuvant therapy Pathological Complete
More informationIntroduction to Clinical Trials - Day 1 Session 2 - Screening Studies
Introduction to Clinical Trials - Day 1 Session 2 - Screening Studies Presented July 23, 2018 Susanne J. May Department of Biostatistics University of Washington Daniel L. Gillen Department of Statistics
More informationMicke et al. Radiation Oncology (2018) 13:71 https://doi.org/ /s y
Micke et al. Radiation Oncology (2018) 13:71 https://doi.org/10.1186/s13014-018-1025-y RESEARCH Open Access Radiotherapy for calcaneodynia, achillodynia, painful gonarthrosis, bursitis trochanterica, and
More informationThank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS.
Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationProf. Dr. Aydın ÖZSARAN
Prof. Dr. Aydın ÖZSARAN Adenocarcinomas of the endometrium Most common gynecologic malignancy in developed countries Second most common in developing countries. Adenocarcinomas, grade 1 and 2 endometrioid
More informationSERUM SELENIUM AND THE RISK OF PROSTATE CANCER. A Research Project by. Chelsea Stancoff-Hon. Bachelor s of Science in Biology, Newman University, 2005
SERUM SELENIUM AND THE RISK OF PROSTATE CANCER A Research Project by Chelsea Stancoff-Hon Bachelor s of Science in Biology, Newman University, 2005 Submitted to the Department of Physician Assistant and
More informationNIH Public Access Author Manuscript World J Urol. Author manuscript; available in PMC 2012 February 1.
NIH Public Access Author Manuscript Published in final edited form as: World J Urol. 2011 February ; 29(1): 11 14. doi:10.1007/s00345-010-0625-4. Significance of preoperative PSA velocity in men with low
More informationIndex. Note: Page numbers of article titles are in boldface type.
Urol Clin N Am 31 (2004) 379 387 Index Note: Page numbers of article titles are in boldface type. A Acinar proliferation, atypical small, as markers for risk of development of prostate cancer, 229 Acupuncture,
More informationPREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS
ADULT UROLOGY PREVALENCE OF PROSTATE CANCER AMONG HYPOGONADAL MEN WITH PROSTATE-SPECIFIC ANTIGEN LEVELS OF 4.0 ng/ml OR LESS ABRAHAM MORGENTALER AND ERNANI LUIS RHODEN ABSTRACT Objectives. To determine
More informationProstate Cancer Incidence
Prostate Cancer: Prevention, Screening and Treatment Philip Kantoff MD Dana-Farber Cancer Institute Professor of fmedicine i Harvard Medical School Prostate Cancer Incidence # of patients 350,000 New Cases
More informationAntioxidants and Viral Infections: Host Immune Response and Viral Pathogenicity
Review Antioxidants and Viral Infections: Host Immune Response and Viral Pathogenicity Melinda A. Beck, PhD Departments of Pediatrics and Nutrition, University of North Carolina at Chapel Hill, Chapel
More informationElsevier Editorial System(tm) for European Urology Manuscript Draft
Elsevier Editorial System(tm) for European Urology Manuscript Draft Manuscript Number: EURUROL-D-13-00306 Title: Post-Prostatectomy Incontinence and Pelvic Floor Muscle Training: A Defining Problem Article
More informationOptimizing Fertility and Wellness After Cancer. Kat Lin, MD, MSCE
Optimizing Fertility and Wellness After Cancer Kat Lin, MD, MSCE University Reproductive Care University of Washington Nov. 6, 2010 Optimism in Numbers 5-year survival rate 78% for all childhood cancers
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationLip. 1. Introduction. 1.1 General Information and Aetiology
Lip 1. Introduction 1.1 General Information and Aetiology Lips are the external part of the mouth. They are bounded externally by facial skin. On the oral cavity side, they are continuous with buccal mucosa
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationGonadosan Distribution GmbH Römerstr Bregenz Österreich Telefon: Fax:
A-Bregenz, 27.04.2016 To Romanian authorities / to whom it may concern, Römerstrasse 2,, Austria, hereby informs. Fertilovit MT Dietary supplement with zinc and selenium. Zinc contributes to normal fertility
More informationClinical Studies supporting the use of Antioxidants during Chemotherapy and Radiation
Clinical Studies supporting the use of Antioxidants during Chemotherapy and Radiation Poly-MVA ORAC Analysis As you are reading the 5 Clinical Studies below, pay close attention to the list of Antioxidants
More informationSetting The setting was primary care. The economic study was conducted in the USA.
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer Zeliadt S B, Etzioni R D, Penson D F, Thompson I M, Ramsey S D Record Status This is a critical abstract of
More informationCohort D Xentuzumab + abemaciclib + fulvestrant (500 mg/month) Key exclusion criteria RP2D-4 NSCLC. Cohort F Xentuzumab + abemaciclib + fulvestrant
A phase Ib trial of xentuzumab and abemaciclib in patients with locally advanced or metastatic solid tumors, including hormone receptor-positive, HER2-negative breast cancer (plus endocrine therapy) Douglas
More informationSCIENTIFIC OPINION. EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) 2. European Food Safety Authority (EFSA), Parma, Italy
SCIENTIFIC OPINION Scientific Opinion on the substantiation of health claims related to selenium and protection of DNA, proteins and lipids from oxidative damage (ID 277, 283, 286, 1289, 1290, 1291, 1293,
More informationMicronutrients: markers of status to understand function? Susan Fairweather-Tait, Norwich Medical School
Micronutrients: markers of status to understand function? Susan Fairweather-Tait, Norwich Medical School First, some definitions [Bio]marker: a characteristic that is reliably and accurately measured and
More informationSurveillance report Published: 17 March 2016 nice.org.uk
Surveillance report 2016 Ovarian Cancer (2011) NICE guideline CG122 Surveillance report Published: 17 March 2016 nice.org.uk NICE 2016. All rights reserved. Contents Surveillance decision... 3 Reason for
More informationON: STUDY OF THE PREVALENCE OF AUTOIMMUNE THYROID DISEASE IN WOMEN WITH BREAST CANCER. Giovanni Sisti MD, Mariarosaria Di Tommaso MD
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationTrace Minerals and Heavy Metals: Implications in Prostate Cancer
REVIEW ARTICLE Trace Minerals and Heavy Metals: Implications in Prostate Cancer SIA Shah Dept of Surgery & Cancer, Faculty of Medicine, Imperial College London & NHS Hammersmith Hospital, London, United
More informationRequirements for Abstracted Text
Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation
More informationMATERIALS AND METHODS
Primary Triple Androgen Blockade (TAB) followed by Finasteride Maintenance (FM) for clinically localized prostate cancer (CL-PC): Long term follow-up and quality of life (QOL) SJ Tucker, JN Roundy, RL
More informationScottish Medicines Consortium
Scottish Medicines Consortium anastrozole 1mg tablets (Arimidex ) No. (198/05) AstraZeneca UK Ltd New indication: for adjuvant treatment of postmenopausal women with hormone receptorpositive early invasive
More informationA Practical Guide to PET adapted Therapy for Hodgkin Lymphoma
Hello. My name is Peter Johnson. I am a Professor of Medical Oncology in Southampton in the UK and I am speaking today on behalf of Managing Hodgkin Lymphoma, and particularly, I am going to talk about
More informationBreast Cancer After Treatment of Hodgkin's Disease.
Breast Cancer After Treatment of Hodgkin's Disease. Hancock SL, Tucker MA, Hoppe R Journal of the National Cancer Institute 85(1):25-31, 1993 Introduction The risks of second malignancy are increased in
More informationLong Term Results in GIST Treatment
Long Term Results in GIST Treatment Dr. Laurentia Gales Prof. Dr. Rodica Anghel, Dr. Xenia Bacinschi Institute of Oncology Prof Dr Al Trestioreanu Bucharest 25 th RSRMO October 15-17 Sibiu Background Gastrointestinal
More informationThe Association between Vitamin D and Lung Cancer Risk in Finnish Male Smokers. Julia Burkley Briarcliff High School
The Association between Vitamin D and Lung Cancer Risk in Finnish Male Smokers. Julia Burkley Briarcliff High School 2 Burkley Table of Contents Introduction~ Pg. 2 Methods~ Pg. 4 Ethics Statement~ Pg.
More informationPhase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
More informationNCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT
NCIC CLINICAL TRIALS GROUP DATA SAFETY MONITORING COMMITTEE Friday, 1 May 2009 SUMMARY REPORT The NCIC CTG DSMC reviewed the following trials with respect to safety, trial conduct, including accrual, and
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More information